Dr Manuel Castro Cabezas
Manuel Cabezas was research fellow for the Netherlands Heart Foundation from 1989-1992 and earned his PhD-degree (cum laude) in 1993 at the University of Utrecht. He was resident Internal Medicine from 1992-1996 at the St. Antonius Hospital in Nieuwegein and from 1996-1997 at the UMC Utrecht. He registered in Internal Medicine in 1997 and was appointed senior scientist at the Lipoprotein Research Team from Professor Willem Erkelens at the UMC Utrecht. He registered in Endocrinology in 1998 and in Vascular Medicine in 2003. At present he is Senior Consultant in Internal Medicine and Co-Director of the Department of Endocrinology, Diabetes and Vascular Medicine at the Franciscus Gasthuis & Vlietland in Rotterdam. He is chairman of the Thyroid Network South-West Netherlands. He is member of the Board of Endocrinology from the Dutch Society of Internal Medicine in the Netherlands. He received several grants from the Netherlands Heart Foundation, National Scientific Organization (NWO), Zon-MW, Coolsingel Foundation, and from several pharmaceutical companies. He has published over 200 papers in peer reviewed journals dealing with postprandial lipemia, diabetes, insulin resistance, obesity, metabolic syndrome, familial combined hyperlipidemia, HIV lipodystrophy and free fatty acid metabolism. He has published among others in the Journal of Clinical Investigation, Lancet, Annals of Internal Medicine, JACC, ATVB and Atherosclerosis. He was the first to describe the Complement-Lipid Pathway (CLiP), protected by several patents.
His network includes collaborations with different groups in the Netherlands (Erasmus MC in Rotterdam, UMC Leiden and UMC Utrecht), in Spain (Reus, Valencia, Málaga, Córdoba, Madrid), in Canada (University of Alberta, Edmonton) and in Australia (Perth). Dr. Castro Cabezas has participated in different international clinical trials in the fields of lipid management, diabetes and obesity. He has supervised 12 PhD students, several Post Docs and numerous postgraduate students. He is currently director of research at the department of Internal Medicine at FG&V with focus on “Inflammation and Atherosclerosis”. He has initiated and supervised many different clinical trials (FRANCIS, REAL-CAD, LIVIT-D, DOSFEM, etc). He is editorial Board Member of: Clinica e Investigacion en Arteriosclerosis. Official Journal of the Spanish Atherosclerosis Society, the Latino-American Society of Atherosclerosis and the Ibero-Latin-American Society of Atherosclerosis and Editorial Board member of Atherosclerosis, official journal of the European Atherosclerosis Society and the International Atherosclerosis Society.
Professor Bernard Cheung
Bernard Cheung is Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics in the Department of Medicine at the University of Hong Kong. He graduated from the University of Cambridge and was a British Heart Foundation Junior Research Fellow at Cambridge before taking up lectureships in Sheffield and Hong Kong. In 2007-2009, he held the chair in Clinical Pharmacology and Therapeutics in Birmingham. He heads the Division of Clinical Pharmacology and Therapeutics in the Department of Medicine of the University of Hong Kong. He is an Honorary Consultant Physician of Queen Mary Hospital and the Medical Director of the Phase 1 Clinical Trials Centre. He is the Editor-in-Chief of Postgraduate Medical Journal. Prof Cheung’s main research interest is in cardiovascular diseases and risk factors, including hypertension and the metabolic syndrome.
Dr Jan Willem F Elte
Jan Willem F Elte is an internist-endocrinologist, Fellow of the Royal College of Physicians (FRCP), the American College of Physicians (FACP), the Fellowship of Postgraduate Medicine (London) and European Federation of Internal Medicine (EFIM: Hon). He is (co-) author and editor of publications and books on thyroid, diabetes, obesity, organization of Internal Medicine and differential diagnosis. Dr Elte is a member of the European Board of Internal Medicine, Secretary General of the Foundation for the Development of Internal Medicine in Europe, and a European Medicines Agency Scientific Committee member and expert as an EFIM delegate. He worked in the Sint Franciscus Gasthuis, Rotterdam 1987-2011 (Deputy Head of Training 1991-2006), and 2012-2014 in the Groene Hart Ziekenhuis, Gouda. He was Secretary of the Section of Endocrinology of the NIV (Neth.Ass.Int.Med.) and former Treasurer of the NIV, AEMI (also President of Young AEMIE) and EFIM. He was a Member of the European Board of Endocrinology and Secretary General of the European Federation of Internal Medicine (EFIM) and co-director of the European School of Internal Medicine 2017-2019. He has been a member of the Editorial Boards of The European Journal of Internal Medicine (Founding Deputy Editor), The Postgraduate Medical Journal, Clinical Medicine and Internisten Vademecum (NL). At his retirement in 2011 he was knighted and became Honorary Member of the NIV.
Dr Anho Liem
Dr Liem is a Fellow of the European Society of Cardiology and a Consultant Cardiologist at Sint Franciscus Gasthuis in Rotterdam and in the Department of Cardiology at Leiden University Medical Centre in The Netherlands. Originally from Indonesia, he graduated in medicine at the Rijksuniversiteit in Leiden. He carried out his MD research from 1976-1977 in the Department of Pulmonary Diseases of the Military Hospital Matthijsen in Utrecht and at the Pulmonary Centre at Amersfoort (1976/1977). His Ph.D thesis was on “Intervention on traditional and non-traditional risk factors for atherosclerotic vascular disease” (2003).
He has served on many national working groups on cardiological matters including the Netherlands Working Group on Cardiology, Guidelines Committees on Dyslipidaemia (2015/2017) and Cardiovascular Risk management (2016/2018).
Recent publications
Pluymaekers NAHA et al. RACE 7 ACWAS Investigators. Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1499-1508.
Burggraaf B et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2019;78:335-341.
Bodde MC et al. Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular Disease. Clinical Pharmacology & Therapeutics 2018;104:311-316.
Arslan F, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. Netherlands Heart Journal 2018;26:417-421.
Bodde MC et al. Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular Disease. Clinical Pharmacology & Therapeutics 2018;104:311-316.
Arslan F et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. Netherlands Heart Journal 2018;26:417-421.
Professor Luis Masana
Prof. Dr. Luis Masana Marín was Head of Internal Medicine Department at Sant Joan University Hospital (Reus) in Tarragona, Spain from 1992-2006 and has been Head of the Vascular Medicine and Metabolism Unit and Lipid and Arteriosclerosis Research Unit at Sant Joan University Hospital (Reus) since 2006. He obtained the of Degree of Medicine and Surgery at Barcelona Autonomous University (UAB) in 1976. His PhD thesis at UAB was entitled «HDL and disease» and was obtained in 1980. He trained as a specialist in Internal Medicine at Valld’Hebron Hospital in Barcelona (1977-1981). His post-doctoral stay at the Chemical Pathology Department at Saint Thomas’s Hospital in London (1983-1984) focused on LDL receptor activity and lipoprotein kinetic studies. He has been Professor of Medicine at Rovira i Virgili University (Reus) since 1991.
He is a former President of the Spanish Society of Arteriosclerosis (2000-2004) and a former member of the Executive Committee of the European Atherosclerosis Society.
His fields of interest in research: Genetic dyslipidemias, fatty acid transporters metabolism, biomarkers of dyslipidemia and cardiovascular risk. He is the author of more than 300 scientific articles in the field of dyslipidemias and cardiovascular risk.
Professor Donald Singer
Donald Singer is a Clinical Pharmacologist interested in new approaches to personalising medicine and in public understanding of health and drugs. He is President of the Fellowship of Postgraduate Medicine and Chair of healthy heart charity the Cardiovascular Research Trust, London, UK. He trained in renal medicine at the Royal Postgraduate Medical School, London and went on to become a clinician and researcher at Charing Cross and Westminster Medical School, St George’s Medical School, Imperial College at Harefield and Warwick Medical School. He has also worked as a clinical pharmacologist for Yale School of Medicine within US-AID and CDC-supported programmes in Rwanda. @HealthMed
Professor Gerald Tomkin
Professor Gerald Tomkin is a Consultant Endocrinologist/Diabetologist based in Beacon Consultants Clinic in Dublin, Ireland
He is a graduate of Trinity College Dublin and Professor of Diabetes and Endocrinology. He spent time training in the UK and USA before coming back to Dublin as a Consultant Physician to The Adelaide and Meath Hospital Dublin (Tallaght Hospital). His main research interests have been focused on cholesterol metabolism in diabetes, obesity and the interaction of bile with glucose protein and fat metabolism.
Gerald Tomkin is president of Diabetes Ireland and has been a Vice-President of the European Association for the Study of Diabetes (EASD) and President of the Association of Physicians of Great Britain and Ireland, President of the Irish Hyperlipidaemia Association and Director of Education, The Royal College of Physicians in Ireland.
Gerald Tomkin has numerous publications in peer reviewed journals. He has been an invited speaker in many countries.
The Healthy Heart Charity 